IONETIX

IONETIX is leveraging its proprietary cyclotron technology platform for isotope production, along with an expanding network of GMP radiopharmaceutical manufacturing sites, to support the development and commercialization of Targeted Alpha Therapy (TAT). TAT is an emerging cancer treatment that utilizes alpha radionuclides to deliver high-energy alpha particles to cancer cells and the tumor microenvironment for cancer therapy while sparing surrounding healthy tissue.